NCT06201689

Brief Summary

A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on fatigue and related health outcomes

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,543

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 31, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 11, 2024

Completed
21 days until next milestone

Study Start

First participant enrolled

February 1, 2024

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 10, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 10, 2025

Completed
Last Updated

July 14, 2025

Status Verified

July 1, 2025

Enrollment Period

1.4 years

First QC Date

December 31, 2023

Last Update Submit

July 10, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in fatigue

    Mean difference in fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 8A (scale 8-40; where higher scores correspond to more severe fatigue)

    6 weeks

Secondary Outcomes (5)

  • Change in cognitive function

    6 weeks

  • Change in sleep

    6 weeks

  • Minimal clinically important difference (MCID) in fatigue

    6 weeks

  • Minimal clinically important difference (MCID) in cognitive function

    6 weeks

  • Minimal clinically important difference (MCID) in sleep

    6 weeks

Other Outcomes (2)

  • Change in mood (emotional distress-depression)

    6 weeks

  • Change in at-home (direct-to-consumer) specimen assays

    6 weeks

Study Arms (18)

Placebo Control 1

PLACEBO COMPARATOR

Energy Product Form 1 - control

Dietary Supplement: Energy Placebo Control Form 1

Active Product 1.1

EXPERIMENTAL

Energy Product Form 1 - active product 1

Dietary Supplement: Energy Active Study Product 1.1 Usage

Active Product 1.2

EXPERIMENTAL

Energy Product Form 1 - active product 2

Dietary Supplement: Energy Active Study Product 1.2 Usage

Placebo Control 2

PLACEBO COMPARATOR

Energy Product Form 2 - control

Dietary Supplement: Energy Placebo Control Form 2

Active Product 2.1

EXPERIMENTAL

Energy Product Form 2 - active product 1

Dietary Supplement: Energy Active Study Product 2.1 Usage

Placebo Control 3

PLACEBO COMPARATOR

Energy Product Form 3 - control

Dietary Supplement: Energy Placebo Control Form 3

Active Product 3.1

EXPERIMENTAL

Energy Product Form 3 - active product 1

Dietary Supplement: Energy Active Study Product 3.1 Usage

Placebo Control 4

PLACEBO COMPARATOR

Energy Product Form 4 - control

Dietary Supplement: Energy Placebo Control Form 4

Active Product 4.1

EXPERIMENTAL

Energy Product Form 4 - active product 1

Dietary Supplement: Energy Active Study Product 4.1 Usage

Active Product 4.2

EXPERIMENTAL

Energy Product Form 4 - active product 2

Dietary Supplement: Energy Active Study Product 4.2 Usage

Active Product 4.3

EXPERIMENTAL

Energy Product Form 4 - active product 3

Dietary Supplement: Energy Active Study Product 4.3 Usage

Active Product 5.1.1

EXPERIMENTAL

Energy Product Form 5.1 - active product 1

Dietary Supplement: Energy Active Study Product 5.1.1 Usage

Placebo Control 5.1.0

PLACEBO COMPARATOR

Energy Product Form 5.1 - control

Dietary Supplement: Energy Placebo Control Form 5.1.0

Placebo Control 5.3.0

PLACEBO COMPARATOR

Energy Product Form 5.3 - control

Dietary Supplement: Energy Placebo Control Form 5.3.0

Active Product 5.3.1

EXPERIMENTAL

Energy Product Form 5.3 - active product 1

Dietary Supplement: Energy Active Study Product 5.3.1 Usage

Active Product 5.3.2

EXPERIMENTAL

Energy Product Form 5.3 - active product 2

Dietary Supplement: Energy Active Study Product 5.3.2 Usage

Placebo Control 5.2.0

PLACEBO COMPARATOR

Energy Product Form 5.2 - control

Dietary Supplement: Energy Placebo Control Form 5.2.0

Active Product 5.2.1

EXPERIMENTAL

Energy Product Form 5.2 - active product 1

Dietary Supplement: Energy Active Study Product 5.2.1 Usage

Interventions

Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.

Placebo Control 1

Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.

Active Product 1.1

Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.

Active Product 1.2

Participants will use their Radicle Energy Placebo Control Form 2 as directed for a period of 6 weeks.

Placebo Control 2

Participants will use their Radicle Energy Active Study Product 2.1 as directed for a period of 6 weeks.

Active Product 2.1

Participants will use their Radicle Energy Placebo Control Form 3 as directed for a period of 6 weeks.

Placebo Control 3

Participants will use their Radicle Energy Active Study Product 3.1 as directed for a period of 6 weeks.

Active Product 3.1

Participants will use their Radicle Energy Placebo Control Form 4 as directed for a period of 6 weeks.

Placebo Control 4

Participants will use their Radicle Energy Active Study Product 4.1 as directed for a period of 6 weeks.

Active Product 4.1

Participants will use their Radicle Energy Active Study Product 4.2 as directed for a period of 6 weeks.

Active Product 4.2

Participants will use their Radicle Energy Active Study Product 4.3 as directed for a period of 6 weeks.

Active Product 4.3

Participants will use their Radicle Energy Placebo Control Form 5.0 as directed for a period of 6 weeks.

Placebo Control 5.1.0

Participants will use their Radicle Energy Active Study Product 5.1.1 as directed for a period of 6 weeks.

Active Product 5.1.1

Participants will use their Radicle Energy Placebo Control Form 5.3 as directed for a period of 6 weeks.

Placebo Control 5.3.0

Participants will use their Radicle Energy Active Study Product 5.3.1 as directed for a period of 6 weeks.

Active Product 5.3.1

Participants will use their Radicle Energy Active Study Product 5.3.2 as directed for a period of 6 weeks.

Active Product 5.3.2

Participants will use their Radicle Energy Placebo Control Form 5.2 as directed for a period of 6 weeks.

Placebo Control 5.2.0

Participants will use their Radicle Energy Active Study Product 5.2.1 as directed for a period of 6 weeks.

Active Product 5.2.1

Eligibility Criteria

Age21 Years - 105 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities. Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
  • Resides in the United States
  • Endorses more energy/less fatigue as a primary desire
  • Has the opportunity for at least 20% improvement in their primary health outcome
  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

You may not qualify if:

  • Report being pregnant, trying to become pregnant, or breastfeeding
  • Unable to provide a valid US shipping address and mobile phone number
  • Reports current enrollment in another clinical trial
  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
  • Unable to read and understand English
  • Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
  • Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. NYHA (New York Heart Association) Class Ill or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
  • Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOls (monoamine oxidase inhibitors), or thyroid products
  • Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s)
  • Lack of reliable daily access to the internet

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Radicle Science, Inc

Del Mar, California, 92014, United States

Location

Related Links

MeSH Terms

Conditions

Fatigue

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Emily K. Pauli, PharmD

    Radicle Science Inc.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Participants will be stratified based on gender at birth, then randomized to one of the study arms
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 31, 2023

First Posted

January 11, 2024

Study Start

February 1, 2024

Primary Completion

July 10, 2025

Study Completion

July 10, 2025

Last Updated

July 14, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Data will not be shared with researchers outside of Radicle Collaborators on this study.

Locations